Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

294.76 -3.49 (-1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
55 56 Next >
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Most Dow stocks are strong investments but these 7 stand out at the moment as the macroenvironment trends positive again. 
Via InvestorPlace
Topics Stocks
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
Via Benzinga
7 Reliable Blue-Chip Stocks That Cannot Miss
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now. 
Via InvestorPlace
Amgen Unusual Options Activity
Via Benzinga
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
How Is The Market Feeling About Amgen?
Via Benzinga
Check Out What Whales Are Doing With AMGN
Via Benzinga
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with... 
Via Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
Dow Jones Industrial Average Closes Above 40,000 In Quiet Friday Climb
The Dow Jones Industrial Average closed above the 40,000.00 major handle for the first time ever after markets wound down a hectic trading week that saw rate cut hopes return to the forefront after US... 
Via Talk Markets
Topics Economy Stocks
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly's biggest growth drivers today are its weight loss drugs. 
Via The Motley Fool
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason. 
Via InvestorPlace
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
FDA approves Amgen's Imdelltra for treating ES-SCLC, based on response rate and DoR in clinical studies. Approval may depend on further trials. 
Via Benzinga
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug? 
Via The Motley Fool
S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally
The S&P 500, Nasdaq 100 and Dow Jones Industrial Average indices all shattered fresh all-time highs Wednesday, driven by a benign inflation report that boosted risk sentiment among bullish investors. 
Via Benzinga
Topics Economy Stocks
The 3 Best Dow Stocks to Buy in May 2024
The Dow Jones Industrial Average has been on a hot streak this month. Here are the three best Dow stocks to buy. 
Via InvestorPlace
Topics Stocks
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
The biotech's pipeline extends far beyond this exciting weight-loss product. 
Via The Motley Fool
5 Stocks Driving Dow's Market-Beating Performance
While 27 of the 30 members of the Dow Jones Index have performed well over the last seven days, we have highlighted five of them that have been leading the way higher. 
Via Talk Markets
Topics Stocks
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
Trade Desk To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Wall Street Stares At Weaker Open On Rate Anxiety, Hopes For Better Earnings: Analyst Pencils Key S&P 500 Support Level
Trading in U.S. index futures suggests stocks may be off to a lackluster start again on Thursday. 
Via Benzinga
Topics Stocks
Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street
Discover the reasons behind three stocks attracting investor attention as they stand on the precipice of future growth. 
Via InvestorPlace
Dow Jones Industrial Average Pushes Higher On Wednesday Despite Tepid Risk Appetite
Via Talk Markets
Topics Stocks
3 Tried and True Dividend Stocks to Buy for Your Portfolio
These dividend stocks to buy represent time-tested companies with significant growth potential. Dive in now to strengthen your portfolio. 
Via InvestorPlace
The Option Market Shows The Way Through This Low-Volume, Fed-Driven Melt-Up
The S&P 500 ended today’s session a little more than 1% higher than where it started. At the same time, trading volume in equities has been very light. 
Via Talk Markets
Topics Stocks
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga
Market Briefing For Monday, May 6, 2024
So prospects for a Fed rate-cut are enhanced by 'mediocre or bad' news on Jobs and Manufacturing fronts. Not a lot; but helps as at least it's not particularly more inflationary; and not a bad... 
Via Talk Markets
Topics Economy
Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update
As the demand for obesity drugs continues to surge, biopharma companies are eagerly seizing the opportunity to capitalize on the trend. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.